Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 32 PAGES: 41

More Info
									            Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic SWOT
                                     Analysis Review
        Reference Code: GDPH59410FSA                                                                                                                          Publication Date: JAN 2014

       Table of Contents
       Table of Contents ............................................................................................................................................................................... 1
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 5
       Avanir Pharmaceuticals, Inc. - Key Facts ........................................................................................................................................... 5
       Avanir Pharmaceuticals, Inc. - Key Employees .................................................................................................................................. 6
       Avanir Pharmaceuticals, Inc. - Key Employee Biographies ................................................................................................................ 7
       Avanir Pharmaceuticals, Inc. - Major Products and Services ............................................................................................................. 8
       Avanir Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 9
          Avanir Pharmaceuticals, Inc., Pipeline Products by Therapy Area ................................................................................................. 9
          Avanir Pharmaceuticals, Inc., Pipeline Products by Development Phase ..................................................................................... 10
       Avanir Pharmaceuticals, Inc. - History .............................................................................................................................................. 12
       Avanir Pharmaceuticals, Inc. - Company Statement ........................................................................................................................ 14
       Avanir Pharmaceuticals, Inc. - Locations And Subsidiaries .............................................................................................................. 17
          Head Office ................................................................................................................................................................................... 17
       Section 2 – Company Analysis ......................................................................................................................................................... 18
       Avanir Pharmaceuticals, Inc. - Business Description ....................................................................................................................... 18
       Avanir Pharmaceuticals, Inc. - Corporate Strategy........................................................................................................................... 19
       Avanir Pharmaceuticals, Inc. - SWOT Analysis ................................................................................................................................ 20
          SWOT Analysis - Overview........................................................................................................................................................... 20
          Avanir Pharmaceuticals, Inc. - Strengths ...................................................................................................................................... 20
             Strength - Sturdy Research and Development Activities ........................................................................................................... 20
             Strength - Strong Patent and Intellectual Property Protection ................................................................................................... 20
          Avanir Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................. 20
             Weakness - Concentrated Geographical Presence .................................................................................................................. 20
             Weakness - Dependence on Third-Party .................................................................................................................................. 20
             Weakness - History of net losses .............................................................................................................................................. 21
          Avanir Pharmaceuticals, Inc. - Opportunities ................................................................................................................................ 21
             Opportunity - Product Pipeline .................................................................................................................................................. 21
             Opportunity - Strategic Agreements .......................................................................................................................................... 21
             Opportunity - Market Potential – CNS Therapy ......................................................................................................................... 21
             Opportunity - Changing Demographics ..................................................................................................................................... 22
             Opportunity - Emerging Markets ............................................................................................................................................... 22
          Avanir Pharmaceuticals, Inc. - Threats ......................................................................................................................................... 22
             Threat - Product Liability Claims ............................................................................................................................................... 22
             Threat - Increasing Counterfeit Products................................................................................................................................... 22
             Threat - Stringent Government Regulations .............................................................................................................................. 23
             Threat - Competitive Pressures ................................................................................................................................................. 23
       Avanir Pharmaceuticals, Inc. - Key Competitors .............................................................................................................................. 24
       Section 3 – Company Financial Ratios ............................................................................................................................................. 25
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 25


Avanir Pharmaceuticals, Inc. (AVNR) - Financial and Strategic                                                                                                  Reference Code: GDPH59410FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
       Performance Chart ........................................................................................................................................................................... 27
       Financial Performance...................................................................................................................................................................... 27
       Financial Ratios - Interim Ratios....................................................................................................................................................... 28
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 29
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 30
          Avanir Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014............................................... 30
          Avanir Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 .............................................. 31
       Avanir Pharmaceuticals, Inc., Recent Deals Summary .................................................................................................................... 32
       Section 5 – Company’s Recent Developments ................................................................................................................................ 33
          Avanir Pharmaceuticals, Inc., Recent Developments ................................................................................................................... 33
             Jan 13, 2014: Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information ............... 33
             Jan 06, 2014: Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference.................................. 33
             Dec 10, 2013: Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results ......... 33
             Nov 26, 2013: Avanir Pharmaceuticals to Participate in Two Conferences in December.......................................................... 34
             Nov 08, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)......................... 34
             Oct 29, 2013: Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information .................... 35
             Oct 23, 2013: Avanir Pharmaceuticals to Host Investor Day on October 29, 2013 ................................................................... 35
             Oct 04, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ......................... 35
             Sep 04, 2013: Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)......................... 35
             Aug 22, 2013: Avanir Pharmaceuticals Announces Publication of 'PRISM' Pseudobulbar Affect Registry Findings................. 36
       Section 6 – Appendix .............................................................................................
								
To top